Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935294 · ClinicalTrials.gov registry record · Phase 1
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
A Phase 1 study of Healthy and Renal Dysfunction, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 4
- Study locations
NCT04935294 is a Phase 1 study of Healthy and Renal Dysfunction that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT04935294, a Phase 1 study of Healthy and Renal Dysfunction, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 4
- Study locations
Study Summary
This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to demographically-matched healthy participants with normal renal function.
Conditions Studied
Interventions
- DRUG Danicopan
Study Locations (4)
Florida
- Clinical Trial Site - Miami
- Clinical Trial Site - Orlando
Minnesota
- Clinical Trial Site - Minneapolis
- Clinical Trial Site - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04935294
The ClinicalTrials.gov registry entry for NCT04935294 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Danicopan is the first listed.
NCT04935294 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04935294 about?
NCT04935294 is a clinical study titled "Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction". This was an open-label, nonrandomized, multi-center, single-dose, parallel group study to evaluate the effect of severe renal impairment (RI) on the safety, tolerability, pharmacokinetics, and pharmacodynamics of danicopan (ACH-0144471) compared to demographically-matched healthy participants with n...
What is the current status of trial NCT04935294?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-01-24. Estimated completion is 2018-05-29.
What conditions does trial NCT04935294 study?
This clinical trial studies the following conditions: Healthy, Renal Dysfunction.
What interventions are being tested in trial NCT04935294?
The interventions under investigation include: Danicopan (DRUG).
Who is sponsoring clinical trial NCT04935294?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04935294 being conducted?
This trial has 4 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.